WO2002064160A3 - Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof - Google Patents

Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof Download PDF

Info

Publication number
WO2002064160A3
WO2002064160A3 PCT/US2002/001125 US0201125W WO02064160A3 WO 2002064160 A3 WO2002064160 A3 WO 2002064160A3 US 0201125 W US0201125 W US 0201125W WO 02064160 A3 WO02064160 A3 WO 02064160A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
vascular proliferation
inhibit vascular
patient
inhibit
Prior art date
Application number
PCT/US2002/001125
Other languages
French (fr)
Other versions
WO2002064160A8 (en
WO2002064160A2 (en
Inventor
Culler Michael Dewitt
Romano Danesi
Guido Bocci
Mario Deltacca
Original Assignee
Sod Conseils Rech Applic
Culler Michael Dewitt
Romano Danesi
Guido Bocci
Mario Deltacca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002243552A priority Critical patent/AU2002243552C1/en
Priority to US10/466,152 priority patent/US7084117B2/en
Priority to KR10-2003-7009238A priority patent/KR20030068585A/en
Priority to NZ526676A priority patent/NZ526676A/en
Application filed by Sod Conseils Rech Applic, Culler Michael Dewitt, Romano Danesi, Guido Bocci, Mario Deltacca filed Critical Sod Conseils Rech Applic
Priority to IL15650602A priority patent/IL156506A0/en
Priority to CA002433785A priority patent/CA2433785C/en
Priority to EP02709045A priority patent/EP1409007A2/en
Priority to JP2002563953A priority patent/JP4099065B2/en
Priority to CZ20031695A priority patent/CZ20031695A3/en
Priority to HU0302732A priority patent/HUP0302732A2/en
Priority to PL36187902A priority patent/PL361879A1/en
Publication of WO2002064160A2 publication Critical patent/WO2002064160A2/en
Publication of WO2002064160A8 publication Critical patent/WO2002064160A8/en
Priority to NO20033117A priority patent/NO20033117L/en
Publication of WO2002064160A3 publication Critical patent/WO2002064160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)

Abstract

The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.
PCT/US2002/001125 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof WO2002064160A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002433785A CA2433785C (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
KR10-2003-7009238A KR20030068585A (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
NZ526676A NZ526676A (en) 2001-01-12 2002-01-14 Pharmaceutical compositions comprising somatostatin type-1 receptor agonists which inhibit vascular proliferation and method of use thereof
JP2002563953A JP4099065B2 (en) 2001-01-12 2002-01-14 Pharmaceutical composition for inhibiting vascular growth and method of use thereof
IL15650602A IL156506A0 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
US10/466,152 US7084117B2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EP02709045A EP1409007A2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
AU2002243552A AU2002243552C1 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
CZ20031695A CZ20031695A3 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
HU0302732A HUP0302732A2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
PL36187902A PL361879A1 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
NO20033117A NO20033117L (en) 2001-01-12 2003-07-08 Pharmaceutical compositions that inhibit vascular proliferation and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26143901P 2001-01-12 2001-01-12
US60/261,439 2001-01-12
US27529401P 2001-03-13 2001-03-13
US60/275,294 2001-03-13

Publications (3)

Publication Number Publication Date
WO2002064160A2 WO2002064160A2 (en) 2002-08-22
WO2002064160A8 WO2002064160A8 (en) 2003-01-30
WO2002064160A3 true WO2002064160A3 (en) 2004-02-19

Family

ID=26948607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001125 WO2002064160A2 (en) 2001-01-12 2002-01-14 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof

Country Status (15)

Country Link
US (1) US7084117B2 (en)
EP (1) EP1409007A2 (en)
JP (1) JP4099065B2 (en)
KR (1) KR20030068585A (en)
CN (1) CN1531441A (en)
AU (1) AU2002243552C1 (en)
CA (1) CA2433785C (en)
CZ (1) CZ20031695A3 (en)
HU (1) HUP0302732A2 (en)
IL (1) IL156506A0 (en)
NO (1) NO20033117L (en)
NZ (1) NZ526676A (en)
PL (1) PL361879A1 (en)
RU (1) RU2288739C2 (en)
WO (1) WO2002064160A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109166B1 (en) * 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
CA2450660C (en) 2001-06-13 2011-08-16 Magnachem International Laboratories, Inc. Lactone formulations and method of use
MXPA03012042A (en) * 2001-06-25 2006-05-22 Il Consorzio Ferrara Richerche Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof.
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US7098187B2 (en) * 2002-09-13 2006-08-29 Attenuon, Llc Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
WO2004039403A1 (en) * 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. Remedy for corneal failure
US7323495B2 (en) 2002-11-05 2008-01-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
WO2005056520A1 (en) * 2003-12-12 2005-06-23 Oy Juvantia Pharma Ltd Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
CN1317031C (en) * 2005-09-14 2007-05-23 上海第二医科大学附属新华医院 Efficient mixture preparation for intensifying solid tumor cell chemical therapeutic sensitivity
JP2011512215A (en) 2008-02-21 2011-04-21 エグザカトゥ Implantable medical device with a protective / holding layer for active ingredients or drugs, especially for water-soluble ones
EP2507310B1 (en) 2009-12-01 2017-09-06 Bridgestone Corporation Modified rubber compositions and methods of preparation
FR3052075B1 (en) 2016-06-01 2022-01-07 Hexacath INFUSION CATHETER DEVICE FOR TREATING AT LEAST PARTIAL OR COMPLETE OBSTRUCTION IN A DUCT, SUCH AS BODY DUCT

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007398A2 (en) * 1994-09-02 1996-03-14 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Sustained release of peptides from pharmaceutical compositions
WO1999049884A1 (en) * 1998-03-27 1999-10-07 Oy Juvantia Pharma Ltd. A method for the prevention of a patient's fibroproliferative vasculopathy
WO1999056769A2 (en) * 1998-05-07 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Inhibition of helicobacter pylori proliferation
WO1999065508A1 (en) * 1998-06-19 1999-12-23 Peptor Ltd. Conformationally constrained backbone cyclized somatostatin analogs
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334434B (en) * 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
JP2002500623A (en) * 1996-11-07 2002-01-08 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー Sprouty proteins and coding sequences
WO2000010552A2 (en) * 1998-08-24 2000-03-02 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
US6903074B1 (en) * 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
US20020103526A1 (en) * 2000-12-15 2002-08-01 Tom Steinke Protective coating for stent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007398A2 (en) * 1994-09-02 1996-03-14 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Sustained release of peptides from pharmaceutical compositions
WO1999049884A1 (en) * 1998-03-27 1999-10-07 Oy Juvantia Pharma Ltd. A method for the prevention of a patient's fibroproliferative vasculopathy
WO1999056769A2 (en) * 1998-05-07 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Inhibition of helicobacter pylori proliferation
WO1999065508A1 (en) * 1998-06-19 1999-12-23 Peptor Ltd. Conformationally constrained backbone cyclized somatostatin analogs
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AAVIK EINARI ET AL: "Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES MAY 2002, vol. 16, no. 7, May 2002 (2002-05-01), pages 724 - 726, XP008014600, ISSN: 1530-6860 *
BARRIE R ET AL: "INHIBITION OF ANGIOGENESIS BY SOMATOSTATIN AND SOMATOSTATIN-LIKE COMPOUNDS IS STRUCTURALLY DEPENDENT", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 4, no. 55, 1993, pages 446 - 450, XP001063285, ISSN: 0022-4804 *
MCCOMBE M ET AL: "EFFECT OF A LONG-ACTING SOMATOSTATIN ANALOGUE (BIM23014) ON PROLIFERATIVE DIABETIC RETINOPATHY: A PILOT STUDY", EYE, ROYAL COLLEGE OF OPHTALMOLOGISTS, LONDON, GB, vol. 5, no. 5, 1991, pages 569 - 575, XP001031225 *

Also Published As

Publication number Publication date
AU2002243552B2 (en) 2005-03-10
NO20033117D0 (en) 2003-07-08
JP4099065B2 (en) 2008-06-11
WO2002064160A8 (en) 2003-01-30
KR20030068585A (en) 2003-08-21
CN1531441A (en) 2004-09-22
AU2002243552C1 (en) 2006-08-31
WO2002064160A2 (en) 2002-08-22
CA2433785A1 (en) 2002-08-22
US20040082517A1 (en) 2004-04-29
HUP0302732A2 (en) 2003-12-29
RU2003124748A (en) 2005-01-10
IL156506A0 (en) 2004-01-04
NZ526676A (en) 2005-03-24
CZ20031695A3 (en) 2004-03-17
EP1409007A2 (en) 2004-04-21
US7084117B2 (en) 2006-08-01
JP2004527483A (en) 2004-09-09
CA2433785C (en) 2009-08-04
PL361879A1 (en) 2004-10-04
NO20033117L (en) 2003-09-04
RU2288739C2 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2005105107A3 (en) Hormone treatment of multiple sclerosis
CA2427227A1 (en) Lactam compound
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
WO2002064160A8 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
SE9603725D0 (en) New teatment
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
MXPA02003484A (en) Synergistic combinations of an nk1.
PT980253E (en) SOMATOSTATIN AND SOMATOSTATIN AGONISTS TO TREAT INSULIN INSULIN AND X SYNDROME
WO2003084503A3 (en) P38 kinase inhibitors for treating mucus hypersecretion_
WO2003018535A3 (en) Novel aminobenzoephenones
MXPA02006511A (en) Complex comprising ocif and polysaccharide.
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
EP1551456A4 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
AU2001262378A1 (en) Method for treating cryptorchidism
WO2003080081A3 (en) Synergistic composition of trans-tetracos-15-enoic acid and apocynin and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PV2003-1695

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 156506

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002709045

Country of ref document: EP

Ref document number: 526676

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2433785

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 02803564X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002563953

Country of ref document: JP

Ref document number: 1020037009238

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002243552

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020037009238

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10466152

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1695

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002709045

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 526676

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002243552

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 526676

Country of ref document: NZ